Navigation Links
Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
Date:3/31/2009

d retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; and any other factors referenced in our other filings with the Securities and Exchange Commission ("SEC") and applicable Canadian regulatory authorities. For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2008 filed with the SEC on Form 10-K.

Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this press release to reflect future results, events or developments.

(C)2009 Angiotech Pharmaceuticals, Inc. All Rights Reserved.

About Angiotech Pharmaceuticals

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicate
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Research and Markets  has announced the addition of the ... report to their offering. This report ... in US$ Thousands. The report provides separate comprehensive analytics for ... , Asia-Pacific , and Rest of ... 2012 through 2020. Market data and analytics are derived from ...
(Date:8/19/2014)... In November 2012, the European Union (EU) ... (PBRER) in a new PSUR – responding to the increasing ... of a drug. Adopted in many regions, the main objectives ... a comprehensive and critical analysis of new or emerging information ... any new evidence of the potential benefits of a drug; ...
(Date:8/18/2014)... 2014) -- A new therapy developed by researchers ... College of Medicine and Columbia University Medical Center ... interventional cardiovascular disease treatment. , The researchers ... molecular therapy could selectively inhibit blood vessel re-narrowing ... procedure using a balloon catheter to open narrowed ...
(Date:8/18/2014)... HIV Infection Drug Market and Pipeline Insight is a ... infection and the number of deaths due to AIDS has ... the globe. It has been estimated that the death rate ... with the rates for children being even much lower. A ... has been the improved access to antiretroviral drugs and therapy ...
Breaking Biology Technology:Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4
... Electric Power Co. and Wisconsin Gas LLC, collectively known ... for relationship management software to automate, track and execute ... than 1.1 million electric customers in Wisconsin and Michigan's ... customers in Wisconsin. As part of a sourcing transformation, ...
... MILWAUKEE - Niceware International, a supplier ... on Monday they have introduced version 4.0 of their ... include support for reading and programming radio frequency identification ... The system's modules are also integrated with Windows programs ...
... services provider, announced Tuesday a new market campaign in ... the campaign will expand the PDS presence in the ... Specialized Technology Partner Certifications from Cisco in the three ... Communications, IP Communications Express, and Wireless. In addition, PDS ...
Cached Biology Technology:
(Date:8/19/2014)... improve students, chances of completing introductory biology courses ... (UH) implemented a comprehensive student success program, employing ... , Through a grant from the Texas ... Biology and Biochemistry embarked on a pilot program ... non-majors and "Introductory Biology" for science majors. These ...
(Date:8/19/2014)... . Wind ... large amount of electricity is to be produced with renewable ... be stored during productive periods so that these fluctuations can ... adequate for the purpose. Science and industry are therefore working ... systems that used to be too expensive or unsophisticated to ...
(Date:8/19/2014)... lemur. It,s not an African Bush Baby or even a ... downright "cool" primate from Southeast Asia. , "It,s really not ... Brown, curator-in-charge at the University of Kansas, Biodiversity Institute. "A ... body; a long tail with a furry tuft at the ... a bit like the disks on the digits of tree ...
Breaking Biology News(10 mins):University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3
... of breast cancer patients have tumours that show rapid ... in all of these cases is the presence of ... membranes. Consequently, these aggressive tumours are referred to as ... IRB Barcelona headed by ICREA researcher Roger Gomis, have ...
... , This release is available in ... unsightly vegetable patches, they can also result in extensive ... this garden pest are similar to those involved in ... Breeding Research in Cologne and the University of Zurich ...
... experts from the European Society on Clinical and ... the International Osteoporosis Foundation (IOF) have published a ... femoral (upper thigh bone) fractures and long-term treatment ... common drug therapy for osteoporotic fracture prevention, prescribed ...
Cached Biology News:The most aggressive forms of breast cancer elude cellular control mechanisms in order to expand 2Mildew-resistant and infertile 2IOF and ESCEO position on atypical femoral fractures and long-term bisphosphonate use 2
Normal human serum, single donor...
... Quality ISO 9001:2000 Certified ... All Precedures Validated, SOP's Training ... Process for All Procedures GLP Documentation Upon ... one stop shopping point for all your ...
Human IL-17D Affinity Purified Polyclonal Ab...
BBS/Glycerol/Casein Block and Diluent - 10X Concentrate, 1 L...
Biology Products: